Atypical BCR-ABL mRNA transcripts in adult Acute lymphoblastic leukemia
暂无分享,去创建一个
T. Lipp | E. Thiel | F. Schneller | H. Rieder | D. Hoelzer | T. Burmeister | N. Gökbuget | J. Eucker | U. Mey | E. Jost | S. Schwartz | H. Thomssen | H. Diedrich | A. Taubald
[1] P. Jonveaux,et al. Identification of an Acute Basophilic Leukaemia Carrying a Rare e6a2 BCR-ABL Transcript , 2006, Acta Haematologica.
[2] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[3] M. Mozziconacci,et al. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib , 2005, Leukemia & lymphoma.
[4] P. Paschka,et al. e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants? , 2005, Leukemia.
[5] S. Lee,et al. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts , 2004, Leukemia.
[6] M. Slovak,et al. Chronic myeloid leukemia with an e13a3 BCR‐ABL fusion: Benign course responsive to imatinib with an RT‐PCR advisory , 2004, American journal of hematology.
[7] P. Paschka,et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C , 2003, Leukemia.
[8] H. Gschaidmeier,et al. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphobla , 2003, Annals of Hematology.
[9] D. Niederwieser,et al. CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall. , 2002, Blood.
[10] R. Kawaguchi,et al. Blast crisis of Philadelphia chromosome‐positive chronic myeloid leukaemia carrying micro‐bcr breakpoint (e19a2 and e191a) , 2002, British journal of haematology.
[11] T. Lipp,et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. , 2002, Blood.
[12] J. Reilly,et al. Are aberrant BCR–ABL transcripts more common than previously thought? , 2000, British journal of haematology.
[13] G. Saglio,et al. The e19a2 bcr/abl breakpoint in acute lymphoblastic leukaemia. , 2000, British Journal of Haematology.
[14] J. Melo,et al. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.
[15] A. Borkhardt,et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. , 1996, Leukemia.
[16] E. Thiel,et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction , 1991, The Lancet.
[17] A. Hagemeijer,et al. A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1990, Leukemia.
[18] S. Colla,et al. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease? , 2004, Haematologica.
[19] J. Melo,et al. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. , 1994, Leukemia.